MAX Automation SE
- WKN: A2DA58
- ISIN: DE000A2DA588
- Land: Deutschland
Nachricht vom 13.04.2021 | 18:12
MAX Automation: Supervisory Board resolves on the strategic realignment of the MAX Group and a change in the composition of the Supervisory Board
MAX Automation SE / Key word(s): Strategic Company Decision/Personnel
Ad hoc RELEASE (PURSUANT TO SECTION 17 MAR)
Duesseldorf, 13 April 2021 - The Supervisory Board of MAX Automation SE (ISIN DE000A2DA58), listed in the Prime Standard of the Frankfurt Stock Exchange, resolved today on the new strategic alignment of the Group after intensive discussions during the last months.
MAX Automation SE will realign its business model towards cash flow-oriented investment management. The focus remains on the current core business. Investments over and beyond will be possible in the future.
Support for this orientation is provided by the extensive changes to the Supervisory Board. Moreover, the Supervisory Board is to be increased by one member. The current Chairman of the Supervisory Board, Dr. Christian Diekmann, will step down as Chairman as planned with effect from the end of the forthcoming Annual General Meeting and will also leave the Board to focus fully on his responsibilities as CEO and CFO of the Group in his position as Managing Director. At the Annual General Meeting, it will be proposed to replace him with Mr. Guido Mundt. Dr. Ralf Guckert and Mr. Marcel Neustock will step down from the Board with effect from the end of the forthcoming Annual General Meeting and Mr. Oliver Jaster and Mr. Hartmut Buscher will be proposed to the Annual General Meeting for election as replacements. Dr. Jens Kruse will step down from the Supervisory Board with effect from the end of the forthcoming Annual General Meeting. Dr. Wolfgang Hanrieder will be proposed to the Annual General Meeting for election as his replacement. In addition, it will be proposed to the Annual General Meeting to expand the Supervisory Board by one member and to elect Dr. Nadine Pallas for this purpose.
|Company:||MAX Automation SE|
|Breite Straße 29-31|
|Phone:||+49 (0)211 90991-0|
|Fax:||+49 (0)211 90991-11|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange; BX|
|EQS News ID:||1184307|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 16:37 Allianz: Kursziel 250 Euro
03. Dezember 16:48 Update DocuSign: Minus steigt auf 40 Prozent! Der nächste ...
03. Dezember 17:00 DAX: Der nächste Nackenschlag
03. Dezember 17:54 Börsenpunk: DAX - Angst ist zurück an den Märkten - jetzt trotzdem ...
03. Dezember 18:09 Alibaba, Tencent und Co: Kleiner Crash vorm Wochenende
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021